<HashMap><database>biostudies-literature</database><scores/><additional><submitter>O'Melia MJ</submitter><funding>Susan G. Komen</funding><funding>Foundation for the National Institutes of Health</funding><funding>NCI NIH HHS</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>2179-2195</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8286278</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>70(8)</volume><pubmed_abstract>Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8&lt;sup>+&lt;/sup> T cell immunity to be primed extratumorally in lymphoid tissues and therapeutically leveraged. CD8&lt;sup>+&lt;/sup> T cell viability and responses within the tumor microenvironment (TME) were found to be severely impaired, effects coincident with local immunosuppression that is recapitulated in lymphoid tissues in late stage disease. Prior to onset of a locally suppressed immune microenvironment, however, CD8&lt;sup>+&lt;/sup> T cell priming within lymph nodes (LN) that depended on tumor lymphatic drainage remained intact. These results demonstrate </pubmed_abstract><journal>Cancer immunology, immunotherapy : CII</journal><pubmed_title>Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.</pubmed_title><pmcid>PMC8286278</pmcid><funding_grant_id>S10OD016264</funding_grant_id><funding_grant_id>T32GM008433</funding_grant_id><funding_grant_id>R01CA207619</funding_grant_id><funding_grant_id>S10 OD016264</funding_grant_id><funding_grant_id>CCR15330478</funding_grant_id><funding_grant_id>T32 GM008433</funding_grant_id><funding_grant_id>R01 CA207619</funding_grant_id><funding_grant_id>U01 CA214354</funding_grant_id><funding_grant_id>U01CA214354</funding_grant_id><pubmed_authors>Manspeaker MP</pubmed_authors><pubmed_authors>Thomas SN</pubmed_authors><pubmed_authors>O'Melia MJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.</name><description>Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for antitumor CD8&lt;sup>+&lt;/sup> T cell immunity to be primed extratumorally in lymphoid tissues and therapeutically leveraged. CD8&lt;sup>+&lt;/sup> T cell viability and responses within the tumor microenvironment (TME) were found to be severely impaired, effects coincident with local immunosuppression that is recapitulated in lymphoid tissues in late stage disease. Prior to onset of a locally suppressed immune microenvironment, however, CD8&lt;sup>+&lt;/sup> T cell priming within lymph nodes (LN) that depended on tumor lymphatic drainage remained intact. These results demonstrate </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-04T01:23:55.523Z</modification><creation>2025-04-04T01:23:55.523Z</creation></dates><accession>S-EPMC8286278</accession><cross_references><pubmed>33459842</pubmed><doi>10.1007/s00262-020-02792-5</doi></cross_references></HashMap>